medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2005, Number 3

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2005; 18 (3)

Treatment of multidrug-resistant pulmonary TB: Standardized or individualized therapy?

Laniado-Laborín R

Language: Spanish
References: 19
Page: 206-210
PDF size: 51.02 Kb.


ABSTRACT

Due to the fact that there where no official guidelines for the treatment of multidrug-resistant tuberculosis (MDR-TB), the Mexican health authorities published the TAES-plus guidelines, for the prevention and control of MDR-TB in December 2004. This recommendations, which basically suggest that treatment failures should be managed with standardized empirical regimens, is based in the guidelines of the World Health Organization (WHO) for the treatment of MDR-TB in low-income countries. However, recently, researchers from the same WHO have challenged the efficacy of this policy. Cure rates of failure cases retreated with regimens based on first-line drugs alone are, on average, lower than 50%. Such figures are simply unacceptable. It is known that such low cure rates are due largely to MDR-TB. It is time, therefore, to close the chapter on cases who fail the treatment regimen with first-line drugs and yet receive retreatment regimens based on the same drugs.


REFERENCES

  1. Guía para la atención de pacientes con tuberculosis multifarmacorresistente. Secretaría de Salud. México, DF: SSA;2004.

  2. Garcia-Garcia ML, Ponce de Leon A, Jimenez-Corona ME, et al. Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Arch Intern Med 2000;160:630-636.

  3. Laniado-Laborín R, Cabrales-Vargas N. Tratamiento acortado estrictamente supervisado: Estrategia necesaria pero no suficiente para controlar la tuberculosis en Baja California, México. Elevadas tasas de multidrogorresistencia en el estado. Rev Inst Nal Enf Resp Méx 2000;13:23-27.

  4. Peter CR, Schultz E, Moser K, et al. Drug-resistant pulmonary tuberculosis in the Baja California-San Diego County border population. West J Med 1998; 169:208-213.

  5. WHO/CDS/TB/2003.313 Treatment of tuberculosis: guidelines for national programmes. 3rd edition.

  6. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course of chemotherapy for drug-resistant tuberculosis. Treatment outcomes in 6 countries. JAMA 2000;283:2537-2545.

  7. Seung KJ, Gelmanova IE, Peremitin GG, et al. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis 2004;39:1321-1328.

  8. Quy HT, Lan NT, Borgdorff MW, et al. Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis 2003;7:631-636.

  9. Han LL, Sloutsky A, Canales R, et al. Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens. Int J Tuberc Lung Dis 2005;9:818-821.

  10. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003;348:119-128.

  11. Saravia JC, Appleton SC, Rich ML, Sarria M, Bayona J, Becerra MC. Retreatment management strategies when first-line tuberculosis therapy fails. Int J Tuberc Lung Dis 2005;9:421-429.

  12. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005; 25:564-569.

  13. Caminero JA. Management of TB suspected cases of drug resistant tuberculosis requiring a second treatment. Biomedica 2004;24 Suppl 1:212-227.

  14. Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004;8:361-368.

  15. Salazar-Lezama MA, Torres-Cruz A, Valdez-Vázquez RR, et al. Resultados del tratamiento de tuberculosis resistente en 91 pacientes del Instituto Nacional de Enfermedades Respiratorias: 2001-2003. Rev Inst Nal Enf Respir 2004;17:15-21.

  16. Drobniewski F, Balabanova Y, Coker R. Clinical features, diagnosis, and management of multiple drug-resistant tuberculosis since 2002. Curr Opin Pulm Med 2004;10:211-217.

  17. Caminero JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J 2005;25:928-936.

  18. www.worldbank.org/mx. 1 de agosto, 2005.

  19. Espinal MA. Time to abandon the standard retreatment regimen with first line drugs for failures of standard treatment. Int J Tuberc Lung Dis 2003;7: 607-608.




2020     |     www.medigraphic.com